AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1996621
Drug: Dexamethasone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (4 mg/day) for 4 or 6 days
Trial: 1996621
Drug: Potassium canrenoate
RxNorm normalized name: Potassium canrenoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium canrenoate (200 mg, at 0800 and 1700 h before experimental nights)
Trial: 6324934
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) 20 mg/m2 daily for the entire treatment duration.
Trial: 6324934
Drug: Sequential administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential administration of Tamoxifen (TAM) 20 mg/m2 daily for 15 days followed by Medroxyprogesterone acetate 350 mg/m2 daily for the next 15 days.
Trial: 6324934
Drug: Sequential administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential administration of Tamoxifen (TAM) and Medroxyprogesterone acetate.
Trial: 30840307
Drug: 1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg ketamine (Group K1)
Trial: 30840307
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg ketamine (Group K1.5)
Trial: 30840307
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg ketamine (Group K2)
Trial: 25304641
Drug: Sofosbuvir and
RxNorm normalized name: sofosbuvir and ledipasvir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir and ribavirin combination therapy
Trial: 22997785
Drug: Acupoint heat-sensitive
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint heat-sensitive moxibustion, 50 treatments over 3 months, 30 to 90 minutes each treatment.
Trial: 22997785
Drug: Seretide inhaler,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seretide inhaler, one inhalation twice per day for 3 months.
Trial: 17854448
Drug: Exercise-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise-based treatment designed to accelerate cerebellar development
Trial: 12539003
Drug: Aprotinin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (both doses)
Trial: 1852793
Drug: Fluoxetine (40-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (40-80 mg/d)
Trial: 1852793
Drug: Maprotiline (50-150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maprotiline (50-150 mg/d)
Trial: 31858234
Drug: No hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No hormone therapy (No HT)
Trial: 30453379
Drug: 19 G
RxNorm normalized name: Sharps Collector 19 Gal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 19 G Flex needle
Trial: 27089361
Drug: Glucose (G)
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucose (G)
Trial: 26390724
Drug: Dexamethasone (DEXA)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DEXA) 6 mg/m2
Trial: 26390724
Drug: Methylprednisolone (MePRED)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MePRED) 60 mg/m2
Trial: 24100259
Drug: Aminophylline administration
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline administration
Trial: 24628736
Drug: Vardenafil ODT
RxNorm normalized name: Vardenafil Orally Disintegrating Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil ODT 10 mg
Trial: 19214890
Drug: Lactulose/mannitol (L/M)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactulose/mannitol (L/M) ratio
Trial: 19214890
Drug: Saccharose excretion
RxNorm normalized name: Saccharose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saccharose excretion
Trial: 19214890
Drug: L/M ratio
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L/M ratio in group A (n = 23)
Trial: 15272100
Drug: St. John's
RxNorm normalized name: St. john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St. John's wort (SJW) extract LI 160, 300 mg twice daily for 6 weeks
Trial: 11384792
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) plus aerobic exercise plus usual and customary care
Trial: 11384792
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) plus usual and customary care
Trial: 8491438
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract EGb 761 (50, 100, 150, or 200 mg)
Trial: 24600651
Drug: 1.0 mL
RxNorm normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mL (0.3 mg/mL) recombinant human platelet-derived growth factor BB (rh-PDGF-BB) mixed with bovine or equine matrix
Trial: 24600651
Drug: 1.0 mL
RxNorm normalized name: digoxin 0.25 mg in 1.0 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mL (0.3 mg/mL) recombinant human platelet-derived growth factor BB (rh-PDGF-BB) mixed with equine matrix
Trial: 18583287
Drug: OPCAB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPCAB with cTnT <1 ng/mL
Trial: 18583287
Drug: OPCAB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPCAB with cTnT >=1 ng/mL
Trial: 9014651
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg Ca as CaCO3, consumed between meals 5 days/week for 1 year
Trial: 1569347
Drug: Fleroxacin, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fleroxacin, 400 mg, single oral dose
Trial: 1569347
Drug: Trimethoprim-sulfamethoxazole (TMP‐SMZ),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole (TMP‐SMZ), 160/800 mg, twice daily for 3 days
Trial: 3902176
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg diltiazem
Trial: 3902176
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg diltiazem
Trial: 30044935
Drug: Thawed plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thawed plasma administration
Trial: 26148364
Drug: Ilioinguinal‐iliohypogastric block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ilioinguinal‐iliohypogastric block with 10 ml 0.5% ropivacaine from each side
Trial: 26148364
Drug: Transversus abdominis
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transversus abdominis plane block with 20 ml 0.25% ropivacaine
Trial: 14669282
Drug: Autologous stem
RxNorm normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous stem cell transplantation (ASCT) after hyper-CVAD regimen; high-dose cyclophosphamide (120 mg/kg), total body irradiation, and ASCT.
Trial: 14669282
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with β2-microglobulin (β2m) level ≤ 3 mg/L at diagnosis or transplantation.
Trial: 8901129
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg morphine hydrochloride as Vendal retard film tablets
Trial: 8901129
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg morphine sulphate as Mundidol retard film tablets
Trial: 27095446
Drug: Oral fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fat load test meal (OFTT) with 0.7 g fat/kg body weight (12% SFA, 10% PUFA, 43% MUFA, 10% protein, 25% carbohydrates)
Trial: 27095446
Drug: Oral fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fat load test meal (OFTT)
Trial: 24767004
Drug: Cognitive control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive control therapy (CCT) + active transcranial direct current stimulation (tDCS)
Trial: 24767004
Drug: Cognitive control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive control therapy (CCT)
Trial: 21805294
Drug: Celastrus orbiculatus
RxNorm normalized name: Lotus corniculatus flower volatile oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celastrus orbiculatus extract (COE) at concentrations of 10, 20, 40, 80, and 160 μg/mL
Trial: 17443478
Drug: Dose modifications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose modifications for nonhematologic toxicity
Trial: 9604941
Drug: No Aspirin
RxNorm normalized name: XS No Aspirin PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No Aspirin
Trial: 15309001
Drug: Withheld Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Withheld Aspirin
Trial: 12040470
Drug: G-CSF (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (5 microg/kg starting on the day of infusion)
Trial: 12040470
Drug: G-CSF (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (5 microg/kg starting five days later)
Trial: 12040470
Drug: No G-CSF
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No G-CSF (Control Group)
Trial: 12040470
Drug: G-CSF (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (both arms A and B)
Trial: 12040470
Drug: G-CSF on
RxNorm normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF on day 0 vs day +5
Trial: 9408713
Drug: Clinical trials
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical trials of pharmacologic agents
Trial: 3555036
Drug: Ciprofloxacin therapy
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin therapy (750 to 2,250 mg daily, mean 1,800 mg)
Trial: 3555036
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (tobramycin or azlocillin)
Trial: 31181990
Drug: Immediate Release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate Release (IR) formulation of cilostazol
Trial: 31181990
Drug: Sustained Release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained Release (SR) formulation of cilostazol
Trial: 23906190
Drug: Tamsulosin (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.4 mg) from 1 day before to 14 days after surgery
Trial: 23906190
Drug: No tamsulosin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No tamsulosin treatment (control group)
Trial: 23906190
Drug: Tamsulosin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin treatment
Trial: 23906190
Drug: Tamsulosin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin treatment and control
Trial: 23697477
Drug: Pharmaceutical counseling
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical counseling of hospital medical staff and additional information in the discharge letter for the PCP
Trial: 20977584
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg LC15-0444
Trial: 20977584
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg LC15-0444
Trial: 20977584
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg LC15-0444
Trial: 20977584
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of LC15-0444
Trial: 18940296
Drug: Group-based high-intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-based high-intensity aerobic interval training (exercise group, n = 40), exercised twice a week for 4 months plus 4 consultations with a CHF nurse.
Trial: 12641613
Drug: Spatone Iron‐Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spatone Iron‐Plus (48 ml)
Trial: 10595595
Drug: UL-TG 307
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UL-TG 307 (24 mg daily)
Trial: 25052785
Drug: In-prison substance
RxNorm normalized name: poison ivy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-prison substance use and depression treatments
Trial: 21928226
Drug: Prolonged prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prolonged prednisolone therapy (5-month)
Trial: 15222602
Drug: Therapeutic touch
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic touch treatments (6 sessions)
Trial: 11755284
Drug: Medical food
RxNorm normalized name: Medical food
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical food bar enriched with L-arginine and other nutrients
Trial: 9842980
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of cisapride (10 mg per unit, 20 mg total dose)
Trial: 9842980
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of cisapride (10 mg per unit, 20 mg total dose)
Trial: 2947953
Drug: 10 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 micrograms hepatitis B vaccine
Trial: 7856298
Drug: Both dosages
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both dosages of hepatitis B vaccine
Trial: 30730866
Drug: Parecoxib sodium
RxNorm normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Parecoxib sodium (40 mg) combined with TAP block (150 mg of 0.375% ropivacaine with 5 mg dexamethasone)
Trial: 30730866
Drug: Placebo (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (40 mg) without TAP block
Trial: 25504506
Drug: Arsenic trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Arsenic trioxide transarterial chemoembolization and intravenous administration of arsenic trioxide
Trial: 20921922
Drug: Methylprednisolone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (30 mg/kg intravenously) administered at anesthetic induction
Trial: 19318461
Drug: Increasing anticholinergic
RxNorm normalized name: Anticholinergics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing anticholinergic load from symptom-specific medications
Trial: 16505800
Drug: Bio-adhesive 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bio-adhesive 0.2% chlorhexidine gel applied once after extraction
Trial: 16505800
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no chlorhexidine gel)
Trial: 16505800
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (chlorhexidine gel)
Trial: 11414873
Drug: Staff-implemented treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Staff-implemented treatments designed to experimentally increase intentional communication ability
Trial: 8302763
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg oral dose of fadrozole hydrochloride
Trial: 8302763
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg oral dose of fadrozole hydrochloride
Trial: 8302763
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg oral dose of fadrozole hydrochloride
Trial: 7833101
Drug: Fadrozole hydrochloride
RxNorm normalized name: Chlorpromazine Hydrochloride
DrugBank: Fadrozole (DB16832)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fadrozole hydrochloride (all doses)
Trial: 31550915
Drug: 300,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300,000 IU of intramuscular vitamin D
Trial: 27775998
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg methylprednisolone at induction and 250 mg methylprednisolone before cardiopulmonary bypass
Trial: 26247968
Drug: Chia oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chia oil (16 mL daily) from the third trimester of pregnancy until the first six months of nursing
Trial: 23438946
Drug: Tacrolimus (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus (5 mg) in CYP3A5 expressers
Trial: 21527202
Drug: 1% testosterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% testosterone propionate ointment twice daily for 30 days before surgery
Trial: 19623047
Drug: Blood glucose
RxNorm normalized name: Blood Glucose Book
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood glucose levels < or =1.2 mmol/L
Trial: 16418786
Drug: Oral alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral alendronate (10 mg daily)
Trial: 15054349
Drug: 8.4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8.4 g/day larch arabinogalactan (n=18)
Trial: 15054349
Drug: 8.4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8.4 g/day tamarack arabinogalactan (n=19)
Trial: 11198705
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of intramuscular thiamin
Trial: 11198705
Drug: Other doses
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other doses of intramuscular thiamin
Trial: 3139325
Drug: 3,000 units
RxNorm normalized name: Ocrevus Zunovo, ocsq 23,000 units-920 mg /23 mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3,000 units pro‐urokinase i.c. (group L)
Trial: 26312597
Drug: Teriparatide therapy
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teriparatide therapy
Trial: 18784609
Drug: Maca (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maca (3.5 g/day for 6 weeks)
Trial: 16651830
Drug: Test drug
RxNorm normalized name: URINE TEST DRUGS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test drug (T) - oral desmopressin acetate 400 mug
Trial: 9683118
Drug: Investigational interleukin-2
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Investigational interleukin-2 (IL-2) therapy
Trial: 9160569
Drug: Brofaromine (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brofaromine (a combined MAO‐A inhibitor/5‐HT transport inhibitor)
Trial: 11498312
Drug: Saline at
RxNorm normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline at a rate of 2 mL/min (control group)
Trial: 9921700
Drug: SSRI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRI plus buspirone (open-label poststudy treatment)
Trial: 7519866
Drug: Moclobemide (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moclobemide (various doses)
Trial: 2667326
Drug: Interferon alternating
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alternating with chemotherapy (5-fluorouracil, doxorubicin, mitomycin, and cis-platin)
Trial: 2667326
Drug: Chemotherapy only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy only (5-fluorouracil, doxorubicin, mitomycin, and cis-platin)
Trial: 2667326
Drug: Interferon alternating
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon alternating with chemotherapy
Trial: 2667326
Drug: Both arms
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both arms (Interferon alternating with chemotherapy and Chemotherapy only)
Trial: 31221891
Drug: Clinical decision
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical decision support system (CDSS) for detection of paediatric SIRS; specific dosage and duration not mentioned.
Trial: 31221891
Drug: Routine clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine clinical care decisions; specific dosage and duration not mentioned.
Trial: 26323728
Drug: Dexmedetomidine 0.5μg/kg/10min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 0.5μg/kg/10min infusion
Trial: 26323728
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline infusion (Control Group)
Trial: 23145864
Drug: Lacrimal probing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacrimal probing and irrigation with adjunctive mitomycin-C (1 mL of 0.2 mg/mL, once)